Shots:

• The P-III DISCOVER study involves assessing of Descovy (emtricitabine- 200 mg/tenofovir alafenamide- 25 mg- qd) vs Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in adult male and transgender female with HIV PrEP
• The P-III DISCOVER study results: met its 1EPs of non-inferiority- reduction in time to achieve EC90 of tenofovir diphosphate (TFV-DP) in PBMCs- @4wks. TFV-DP level (98% vs 68%). Additionally- pharmacokinetic data showed Descovy maintains TFV-DP conc. level for a longer time than Truvada
• Descovy is a dual regimen therapy indicated in combination with other ARV for HIV-1 infections in patients weighing at least 35 kg

Click here to read full press release/ article

Ref: Gilead | Image:  Gilead